Market capitalization | $64.78m |
Enterprise Value | $-3.27m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.02 |
EV/Sales (TTM) EV/Sales | -0.13 |
P/S ratio (TTM) P/S ratio | 2.55 |
P/B ratio (TTM) P/B ratio | 0.96 |
Revenue (TTM) Revenue | $25.38m |
EBIT (operating result TTM) EBIT | $-176.88m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
3 Analysts have issued a Adagio Therapeutics Inc forecast:
3 Analysts have issued a Adagio Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 25 25 |
-
|
|
Gross Profit | 21 21 |
1,117%
1,117%
|
|
EBITDA | -174 -174 |
16%
16%
|
EBIT (Operating Income) EBIT | -177 -177 |
15%
15%
|
Net Profit | -170 -170 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Head office | United States |
CEO | William Duke |
Employees | 99 |
Founded | 2020 |
Website | invivyd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.